India : Bajaj Healthcare Ltd., a leading manufacturer of APIs, Intermediates, and Formulations, is pleased to announce its entry into a definitive Contract Development and Manufacturing Organization (CDMO) agreement with esteemed UK/EU-based customers for the supply of 15 Active Pharmaceutical Ingredients (APIs). Under this agreement, BHL will be responsible for the development and supply of these molecules, exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The execution of the CDMO agreement will leverage BHL’s in-house R&D and manufacturing capacities located at Savli Vadodara, Gujarat.
Mr. Anil Jain, Joint Managing Director of Bajaj Healthcare, expressed enthusiasm about the strategic collaboration, highlighting its significance in reaffirming Bajaj Healthcare Ltd.’s commitment to innovation, excellence, and addressing the evolving needs of the pharmaceutical industry. He emphasized that by leveraging their expertise and state-of-the-art infrastructure, they are poised to improve the accessibility and affordability of essential medications worldwide. Mr. Jain further highlighted the company’s cutting-edge in-house Research and Development (R&D) facilities and manufacturing capabilities at Savli, Gujarat, indicating their readiness to deliver exceptional quality and efficiency to meet customer requirements.